Intrapleural agents for pleural infection: fibrinolytics and beyond
Current Opinion in Pulmonary Medicine, 06/04/2012
Rahman NM – Fibrinolytic therapy alone has not been proven to be of use in the treatment of pleural infection. The Multi–Centre Intrapleural Sepsis Trial 2 (MIST2) study provides clear–cut evidence demonstrating improved chest radiographs, and highly suggestive secondary outcomes suggesting improved clinically important outcomes, using a combination of intrapleural tPA and DNase. This novel treatment combination may represent an important step in the understanding and treatment of pleural infection; however, larger clinical studies specifically addressing important clinical outcomes and further laboratory research describing the potential mechanisms of action are now required.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.